Soligenix Inc. Warrant (SNGXW)

Etorro trading 970x250

About Soligenix Inc. Warrant

Address:

Soligenix Inc. Warrant News and around…

Latest news about Soligenix Inc. Warrant (SNGXW) common stock and company :

Soligenix Announces Successful Protection using a Bivalent Thermostabilized Filovirus Vaccine
02 Dec, 2021 Yahoo! Finance

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today 100% protection of non-human primates (NHPs) against lethal Sudan ebolavirus (SUDV) challenge using a bivalent, thermostabilized vaccine formulated in a single vial, reconstituted only with water immediately prior to use. This milestone is part of an ongoing collaboration w

Soligenix Proof of Concept Uncovers Potential Treatment Option for the World's 125 Million Psoriasis Sufferers
30 Nov, 2021 Yahoo! Finance

New York, New York--(Newsfile Corp. - November 30, 2021) - PCG Digital -- Proof of concept in the biopharmaceutical sector is a process. Efficacy tests are performed, results are recorded from each round of clinical trials, and formulation changes are made if necessary. Each iteration moves the treatment closer to an NDA filing, with an end goal of achieving FDA approval. The goal is to gather enough data during trials to make that happen. ...

Soligenix Announces Recent Accomplishments And Third Quarter 2021 Financial Results
12 Nov, 2021 Yahoo! Finance

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended September 30, 2021.

Soligenix Granted Pediatric Investigational Plan Waiver for HyBryte™ in CTCL in the United Kingdom
08 Nov, 2021 Yahoo! Finance

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has been granted a Pediatric Investigation Plan (PIP) product-specific waiver from the Medicines and Healthcare products Regulatory Agency (MHRA) for HyBryte™ (SGX301 or synthetic hypericin), which has successfully concluded a Phase 3 pivotal clinical study for the

Soligenix Announces Publication Demonstrating Enduring Protection of its Thermostable RiVax® Vaccine
04 Nov, 2021 Yahoo! Finance

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today publication of pre-clinical immunogenicity studies for RiVax® (heat stable ricin toxin vaccine) demonstrating enduring protection for at least 12 months post-vaccination. The article titled "Durable Immunity to Ricin Toxin Elicited by a Thermostable, Lyophilized Subunit Vac

Thermostable Vaccine Technology Platform to be Presented at the 6th International Conference on Vaccines Research and Development
01 Nov, 2021 Yahoo! Finance

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Oreola Donini, PhD, Chief Scientific Officer, will be presenting key data from the Company's thermostable vaccine technology platform, including results from the Company's programs for ricin toxin vaccine (RiVax®), COVID-19 vaccine (CiVax™) and filovirus vaccines (targ

Highlights and Insights into Soligenix
13 Oct, 2021 Yahoo! Finance

Dr. Chris Schaber Discusses Soligenix HyBryte(TM) and Thermostabilized Vaccines New York, New York--(Newsfile Corp. - October 13, 2021) - PCG Digital -- In a recent interview with Kristen Kluska, a biotechnology analyst at Cantor, Dr. Chris Schaber, President and CEO of Soligenix (NASDAQ: SNGX), spoke about the latest developments with their synthetic hypericin topical treatment HyBryte™ and the Company's ongoing research and development of thermostabilized vaccine candidates for filoviruses and

HyBryte™ FLASH Study Selected as a 'Top Poster' Winner for Presentation at the National Organization for Rare Disorders' Rare Diseases and Orphan Products Breakthrough Summit
12 Oct, 2021 Yahoo! Finance

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today their poster abstract was selected as a "top abstract winner" and has been accepted for display and presentation at the 2021 National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit to be held virtually on October 18-19, 2021. Ch

Vaccine from Soligenix Could Accelerate Global Recovery from COVID-19 Pandemic
07 Oct, 2021 Yahoo! Finance

COVID-19 Vaccine Candidate Demonstrates Broad Neutralizing Antibody Response Against Beta, Gamma and Delta Variants New York, New York--(Newsfile Corp. - October 7, 2021) - PCG Digital -- Shipping and administering COVID-19 vaccines that need to be stored at sub-zero temperatures is hampering the pandemic recovery efforts of health professionals around the world. Soligenix, Inc (NASDAQ: SNGX), a US-based late-stage biopharmaceutical company, is developing a solution to that problem. The Company

Soligenix Announces Accelerated Publication Demonstrating Efficacy and Broad Neutralizing Activity of its COVID-19 Vaccine in Non-Human Primates
28 Sep, 2021 Yahoo! Finance

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today publication of pre-clinical immunogenicity studies for CiVax™ (heat stable COVID-19 vaccine program) demonstrating durable broad-spectrum neutralizing antibody responses, including against the Beta, Gamma and Delta variants of concern. The article, titled "Protein Vaccine I

Soligenix Invited to Present at the Cantor Fitzgerald Global Healthcare Conference
27 Sep, 2021 Yahoo! Finance

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will participate in a fireside chat hosted by Kristen Kluska, Director, Equity Research, at the Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 29, 2021 at 8:00AM ET. In addi

Soligenix to Advance Synthetic Hypericin Development in Psoriasis
16 Sep, 2021 Yahoo! Finance

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that following the validation of synthetic hypericin's biologic activity in the positive pivotal Phase 3 FLASH (Fluorescent Light Activated Synthetic Hypericin) study in cutaneous T-cell lymphoma (CTCL), as well as positive proof-of-concept (PoC) demonstrated in a small Pha

Soligenix Develops Groundbreaking Vaccine Platform to Target Future Pandemics
14 Sep, 2021 Yahoo! Finance

Soligenix discusses its contribution to addressing future serious public health threats in a podcast New York, New York--(Newsfile Corp. - September 14, 2021) - PCG Digital -- The COVID-19 pandemic has already cost the United States an estimated $16 trillion in lost economic output, and has resulted in the loss of over 600,000 lives. At the end of last month, the country reached the dubious milestone of 39 million diagnosed cases of COVID, however, researchers ...

Is Soligenix (NASDAQ:SNGX) Using Too Much Debt?
13 Sep, 2021 Yahoo! Finance

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

FDA Grants Soligenix Orphan Drug Designation for the Treatment of T-cell Lymphoma
09 Sep, 2021 Yahoo! Finance

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Office of Orphan Products Development of the United States (U.S.) Food and Drug Administration (FDA) has granted orphan drug designation to the active ingredient hypericin for the treatment of T-cell lymphoma, extending the target population beyond cutaneous T-cell

Soligenix: Developing Tools to Tackle the Next Potential Pandemic; PCG Digital Biotech Watch Review
24 Aug, 2021 Yahoo! Finance

Vaccines are known for the stringent cold chain storage requirements necessary to maintain their integrity. In the U.S., maintaining refrigerated or frozen conditions is a simple logistical hurdle. In developing nations, however, vaccine storage is a considerable challenge for the nearly three billion people who live in regions lacking temperature-controlled storage. As new vaccines are engineered, the development of thermally stable vaccines has lagged.

Soligenix Announces Publication Demonstrating Successful Formulation and Heat Stabilization of Filovirus Vaccine Platform for Ebola and Marburg Virus Diseases
23 Aug, 2021 Yahoo! Finance

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today a publication describing the formulation of single-vial platform presentations of monovalent (single antigen), bivalent (two antigens) and trivalent (three antigens) combinations of filovirus vaccine candidates. In collaboration with University of Hawaiʻi at Mānoa (UHM) and

Soligenix Announces Positive Preclinical Data with Multiple Heat Stable Filovirus Vaccine Candidates
18 Aug, 2021 Yahoo! Finance

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today positive data demonstrating the efficacy of multiple filovirus vaccine candidates in NHPs, including thermostabilized multivalent vaccines in a single vial platform presentation. Collaborators at the at the University of Hawaiʻi at Mānoa (UHM) describe the potent efficacy o

Soligenix Announces Recent Accomplishments And Second Quarter 2021 Financial Results
13 Aug, 2021 Yahoo! Finance

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended June 30, 2021.

Who Is Preparing Us for the Next Potential Pandemic?
29 Jul, 2021 Yahoo! Finance

New York, New York--(Newsfile Corp. - July 29, 2021) - -- PCG Digital -- Dr. Fauci said it publicly this week, but we've all been thinking it for months now. COVID-19 did not hit us, "out of the blue." Scientists, medical professionals, and researchers have been expecting this for years. The global pandemic was no surprise to them.It will happen again. That's not prophetic gloom and doom. It's scientific fact. With the number of ...

Soligenix Inc. Warrant (SNGXW) is a NASDAQ Common Stock listed in ,

970x250